Previous 10 | Next 10 |
Over the past week, the S&P 500 rose again by 2.75%, almost recovering from its YTD losses. With economies restarting, novel optimism about vaccines and better-than-feared job losses last week, the stock market is behaving very optimistically. Of course, the biggest reason for this strong ...
SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today at the ASCO Annual Meeting presented a preclinical update for its novel, clinical-stage...
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offerin...
Gamida Cell (NASDAQ: GMDA ) -25% after pricing equity offering. More news on: Gamida Cell Ltd., Gossamer Bio, Inc., Bellerophon Therapeutics, Inc., Stocks on the move, , Read more ...
Turning Point Therapeutics (NASDAQ: TPTX ) has priced its public offering of 5,416,667 common shares at $60.00/share, for expected gross proceeds of ~$325M. More news on: Turning Point Therapeutics, Inc., Healthcare stocks news, , Read more ...
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416...
Turning Point Therapeutics (NASDAQ: TPTX ) has commenced a public offering to issue and sell $250M shares of common stock. More news on: Turning Point Therapeutics, Inc., Healthcare stocks news, , Read more ...
The following slide deck was published by Turning Point Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Turning Point Therapeutics Inc (NASDAQ: TPTX) Q1 2020 Earnings Call May 12, 2020 , 4:30 p.m. ET Operator Continue reading
Turning Point Therapeutics, Inc. (TPTX) Q1 2020 Earnings Conference Call May 12, 2020 4:30 p.m. ET Company Participants Jim Mazzola - SVP, Communication and IR Athena Countouriotis - President and CEO Yi Larson - EVP and CFO Conference Call Participants Corinne Jenkins - Go...
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
Turning Point Therapeutics Inc. Website:
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administ...